KRAS^G12C-Mutated Nonsmall-Cell Lung Cancer: A Phase IIb Trial

This multicenter, single-arm , Phase IIb study assessed the efficacy and safety of glecirasib administered orally at 800 mg daily in patients with locally advanced or metastatic KRASG12C-mutated NSCLC.